Your browser version may not work well with NCBI's Web applications. More information here...
1: Optometry. 2006 Apr;77(4):177-9.Click here to read Links

Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy.

Steinhäuser SL.

Prime Eye Care, Phoenix, Arizona 85021, USA. ssteinhauser@gmail.com

BACKGROUND: The aim of this study is to report an adverse systemic response associated with topical bimatoprost therapy. CASE REPORT: An otherwise healthy 58-year-old woman with primary open-angle glaucoma was started on bimatoprost drops once a day. Bimatoprost is a structural analog of prostaglandin F2 alpha-ethanolamide (PGF2a), a class of compounds that in systemic form has been associated with alterations in serum lipid levels. The patient subsequently experienced a significant decrease in her high-density lipoprotein (HDL) serum levels, which subsequently returned to normal on discontinuation of bimatoprost. CONCLUSIONS: This is the first published report of a possible association between topical bimatoprost therapy and decreased serum HDL levels. Because of the significantly increased risk of cardiovascular disease and morbidity associated with low HDL levels, further study is strongly indicated.

PMID: 16567279 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Bimatoprost Ophthalmic (Lumigan® )

    Bimatoprost is used to treat eye conditions, including glaucoma and ocular hypertension, in which increased pressure can lead to a gradual loss of vision. Bimatoprost is used for patients who cannot use other eye medicat...

  • Bimatoprost Topical (Latisse® )

    Topical bimatoprost is used to treat hypotrichosis (less than the normal amount of hair) of the eyelashes by promoting the growth of longer, thicker, and darker lashes. Topical bimatoprost is in a class of medications ca...

  • Source: AHFS Consumer Medication Information